Takeda's Investigational Compound TAK-536 Enters into Phase 2 Clinical Stage in Japan
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited ("Takeda") announced that its investigational compound TAK-536 has entered into Phase 2 clinical stage in Japan. TAK-536 is an angiotensin receptor blocker (ARB) discovered by Takeda and its mechanism of action is to lower blood pressure by inhibiting action of a vasopressor hormone Angiotensin II.
Results Were Consistent in Patients Switched to Angiox from Other Antithrombin Therapy
- Details
- Category: Product
Patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), or angioplasty, experienced nearly 50 percent less bleeding at 30 days and comparable mortality at one-year when treated with Angiox(R) (bivalirudin) alone compared to unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor (GPI), according to data from the ACUITY trial.
Strategic Acquisition of MedPointe Inc Completed
- Details
- Category: Financial
Meda announced that it had signed an agreement to acquire all shares in MedPointe. This strategic acquisition has now been completed and consolidation of MedPointe starts immediately. Meda plans to give further information on the acquisition and its impact on Meda in the interim report for the third quarter - to be released on 30 October 2007.
Award for Bilobil in Poland
- Details
- Category: Product
The first place in the national competition "Consumer's Laurel 2007" in the category "Drugs for memory improvement" has been won by Krka's Bilobil. As in the last year, also this year Bilobil won the first place in its category.
Journalists from Argentina and Greece win Novo Nordisk Media Prize 2007
- Details
- Category: Novo Nordisk
Journalists Gabriela Navarra from Argentina and Michael Kefalogiannis from Greece won the Novo Nordisk Media Prize 2007 for the best article in lay press and the best TV feature about diabetes, respectively. The awards were presented by the president and CEO of Novo Nordisk, Lars Rebien Sørensen, during a ceremony held on 28 August in Copenhagen.
InferMed appoints Cancer Research UK's Dr Sally Burtles as Observer to the Board
- Details
- Category: Business
InferMed, a leading provider of advanced software solutions for clinical research and practice, has appointed Dr Sally Burtles, Director of Drug Development at Cancer Research UK, as an Observer to the Board.
InferMed has a long-standing relationship with Cancer Research UK, and was backed by the charity at its formation in 1999. A research relationship continues with Cancer Research UK, which remains InferMed's largest institutional shareholder.
Court Rules That Roche Infringes One of Amgen's Erythropoietin Patents
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that the U.S. Federal District Court in Boston granted Amgen's motion for summary judgment and ruled that Roche's pegylated-erythropoietin ("peg-EPO") product will infringe Amgen's EPO pharmaceutical composition patent number 5,955,422. In a separate decision yesterday, the Court also granted summary judgment in favor of Amgen on certain Roche defenses against the patents-in-suit.
More Pharma News ...
- Nexavar Significantly Improved Overall Survival in Phase III Asia-Pacific Liver Cancer Trial
- Pfizer Names Frank A. D'Amelio Chief Financial Officer
- Liraglutide improves glucose control and lowers body weight in two phase 3 studies
- GlaxoSmithKline Signs Contract for its Pandemic Flu Vaccine with UK Government
- Ligand Pharmaceuticals Announces Second Quarter Results
- Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17
- Availability on line of the sanofi-aventis half-year financial report for 2007